Anuh Pharma Q4 FY22 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- The company targets sales of Rs. 600 crores for FY 2023, showing optimism about demand resumption despite currently falling short.
- Plans to introduce five new API products in FY23: Allopurinol, Acebrophylline, Citicoline, Theophylline, and Caffeine, to build growth foundation.
- Focus on increasing market share of existing products and geographic expansion in Vietnam, Japan, and South Korea.
- Approval filings (CEP for Gliclazide, Azithromycin and WHO PQ for Isoniazide) expected to open European market and institutional business, potentially adding Rs. 50 crore in sales within two years post-approval.
- Manufacturing capacity utilization is about 60%, with potential to add 300 tons capacity by machinery addition.
- R&D and compliance (environment, safety, GMP) are key pillars supporting sustainable growth.
- Expect demand improvement post-pandemic and seasonally from June to October (monsoon period).
See what Anuh Pharma management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no mention of any current or planned fundraising through debt or equity in the transcript.
- The company has not indicated plans for new equity issuance or debt raising in the discussion.
- Focus appears to be on operational growth, increasing market share, and capital expenditure mainly related to capacity expansion (Rs. 40 to 50 lakhs in FY23) rather than raising external funds.
- The conversation and queries were more centered around shareholding patterns, buyback suggestions, and realistic growth expectations rather than new fundraising.
- No statements about issuing new shares or raising debts were made during the call or in management's closing remarks.
See what Anuh Pharma management said on order book — free account, 30 seconds.
Capex plans
Yes- The company plans capital expenditure of approximately Rs. 40 to 50 lakhs in FY23 to bring versatility in production capabilities by adding machinery.
- They have previously made CAPEX of Rs. 70 crores in 2019, which expanded manufacturing capacity to 1500 tons; currently utilizing about 60% of this capacity.
- Company focuses on R&D and plans to introduce five new API products in FY23 (Allopurinol, Acebrophylline, Citicoline, Theophylline, and Caffeine) to build a foundation for future growth.
- There is no specific mention of strategic investments, but the company aims to increase market presence geographically (Vietnam, Japan, South Korea) and expand sales in the European market via CEP and WHO PQ filings.
Track Anuh Pharma — get its next earnings analysis in your feed
How does Anuh Pharma rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Anuh Pharma rank in Pharmaceuticals & Biotechnology?
Compare Anuh Pharma against every Pharmaceuticals & Biotechnology company (Q4 FY22) on revenue, margins and earnings-call signals.
Continue your research
What Anuh Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q2 FY27)
11.67% increase. Key results statement takeaways from Natural Capsules Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Sotac Pharmaceuticals (Q2 FY27)
7,654.95 lakhs; Operating margin ≈ 10.68% for HY Sep 2026 . Key results statement takeaways from Sotac Pharmaceuticals Ltd's Q2 FY27 results statement — and how
- Bio Medica Lab (Q2 FY27)
EBITDA for the quarter:** ₹510 lakhs, up 25% year-on-year (YoY). Key results statement takeaways from Bio Medica Laboratories Ltd's Q2 FY27 results statement —
- Syncom Formulations (India) (Q2 FY27)
Quarterly Revenue (Q2 FY 2026-27 ended 30/09/2026):** ₹14,821.08 lakhs (Unaudited) . Key results statement takeaways from Syncom Formulations (India) Ltd's Q2 F